Cancer Drugs Fund requires further reform
BMJ
.
2016 Sep 27:354:i5090.
doi: 10.1136/bmj.i5090.
Authors
Richard Grieve
1
,
Keith Abrams
2
,
Karl Claxton
3
,
Ben Goldacre
4
,
Nicholas James
5
,
Jon Nicholl
6
,
Mahesh Parmar
7
,
Chris Parker
8
,
Jasjeet S Sekhon
9
,
Liam Smeeth
10
,
David Spiegelhalter
11
,
Mark Sculpher
3
Affiliations
1
Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London WC1H 9SH, UK richard.grieve@lshtm.ac.uk.
2
Department of Health Sciences, University of Leicester, Leicester, UK.
3
Centre for Health Economics, University of York, York, UK.
4
Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK.
5
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
6
School of Health and Related Research, University of Sheffield, Sheffield, UK.
7
Medical Research Council Clinical Trials Unit, University College London, London, UK.
8
Institute of Cancer Research: Royal Cancer Hospital, London, UK.
9
Travers Department of Political Science, Department of Statistics, University of California, Berkeley, CA, USA.
10
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine.
11
Statistical Laboratory, Centre for Mathematical Sciences, Cambridge, UK.
PMID:
27677636
DOI:
10.1136/bmj.i5090
No abstract available
Publication types
Editorial
Grants and funding
G106/1173/MRC_/Medical Research Council/United Kingdom
MR/K006584/1/MRC_/Medical Research Council/United Kingdom
MR/M026183/1/MRC_/Medical Research Council/United Kingdom
SRF-2013-06-016/DH_/Department of Health/United Kingdom